Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term pediatric safety follow-up of tacrolimus ointment for atopic dermatitis
NL-OMON30879Phase 4Active, not recruiting
- Sponsor
- Astellas Pharma
- Start
- Aug 2008
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Envarsus XR in atopic dermatitis (AD), sponsored by Astellas Pharma. Primary endpoints: Frequency of all serious adverse events, Total systemic malignancies and 2 more. Started Aug 2008; status: active, not recruiting.
02
Drugs
Envarsus XR
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NL-OMON30879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON30879.